A Randomized, Open-label, Multicenter, Parallel-group Study to Compare the Efficacy, Safety and Resource Utilization of a Remifentanil/Propofol Analgesia/Sedation Regimen Versus a Sufentanil/Propofol Analgesia/Sedation Regimen in Mechanically Ventilated Intensive Care Patients Requiring Analgesia and Sedation for up to 7 Days
Phase of Trial: Phase IV
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Remifentanil (Primary) ; Propofol; Sufentanil
- Indications Pain
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 24 Jul 2007 Status changed from initiated to discontinued.
- 30 Jan 2007 New trial record.